Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

This study has been terminated.
(Higher hemorrhage rates of Abciximab in ABESST II trial)
Sponsor:
Collaborators:
Schweizerische Herzstiftung
Eli Lilly and Company
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00126139
First received: July 29, 2005
Last updated: May 1, 2007
Last verified: May 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2005
  Estimated Primary Completion Date: No date given